A major new study has sent a clear message to people with type 2 diabetes: stopping certain medications could be a high-stakes gamble for your heart. The research found that discontinuing this specific class of drugs nearly doubles the risk of heart attack
or stroke.
The Alarming Findings
A recent large-scale study published in The Lancet Regional Health – Europe has highlighted a significant danger for patients with type 2 diabetes. After analyzing the health records of over 80,000 people in Italy, researchers found a stark association: patients who stopped taking a class of drugs known as GLP-1 receptor agonists had approximately double the risk of suffering a non-fatal heart attack, a non-fatal stroke, or dying from any cause compared to those who continued their treatment. To put it in perspective, the rate of these major adverse events was about four per 100 people each year among those who discontinued the medication, versus only two per 100 people for those who remained on it.
Which Drugs Are in Focus?
The study focused on glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. This modern class of drugs has become a cornerstone in managing type 2 diabetes. They work by mimicking a natural gut hormone to help regulate blood sugar, and many also lead to weight loss. The drugs examined in the Italian study primarily included liraglutide and dulaglutide, though a small number of semaglutide (widely known by brand names like Ozempic) users were also included. These medications are prized not just for their blood sugar control but for their proven cardiovascular benefits, which this new study suggests are lost when the treatment is stopped.
Why Do People Stop Taking Them?
Despite their benefits, a surprisingly high number of patients—up to 60% in this study—stop taking these drugs, often within the first year. The reasons for discontinuation are varied. Common factors include gastrointestinal side effects like nausea, the high cost of the medications, a perceived lack of effectiveness, or concerns about other potential side effects. In some cases, patients may feel better and mistakenly believe they no longer need the medication, a decision that can have unseen and dangerous consequences. This study underscores that the protective effects of these drugs are not permanent and depend on continued use.
Expert Cautions and Context
It is crucial to understand the nature of this research. As an observational study, it shows a strong association, but it cannot prove that stopping the drug directly causes heart attacks or strokes. Experts urge caution, noting that people who stop their medication might differ from those who continue in other ways. For example, they might have other health issues, poorer overall medication adherence, or socioeconomic factors that put them at a higher underlying risk to begin with. However, the findings align with what cardiologists already know about the protective nature of these drugs: when you remove the protection, the underlying risks can re-emerge. The risk appeared even more pronounced in patients with obesity.
What This Means for Patients in India
For the millions of people in India living with type 2 diabetes, this study serves as a powerful reminder about the importance of medication adherence. The findings strongly suggest that GLP-1 drugs are not a shortterm fix but a longterm management strategy for a chronic condition. The cardiovascular protection they offer is only active as long as you are taking them. Abruptly stopping this or any other prescribed medication for a chronic illness like diabetes can lead to a rapid loss of benefits and an increase in health risks. Uncontrolled blood sugar itself damages blood vessels and elevates the risk of heart disease over time.
